Company:  ALIMERA SCIENCES INC (ALIM)
Form Type:  10-K
Filing Date:  3/30/2012 
CIK:  0001267602 
Address:  6120 WINDWARD PARKWAY
STE 290
 
City, State, Zip:  ALPHARETTA, Georgia 30005 
Telephone:  (678) 990-5740 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$5.87  
Change: 
0.02 (0.34%)  
Trade Time: 
Jul 09  
Market Cap: 
$236.71M
Description of Business
Alimera Sciences, Inc., and its subsidiaries (we, Alimera or the Company), is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. We are presently focused on diseases affecting the back of the eye, or retina, because we believe these diseases are not well treated with current therapies and represent a significant market opportunity. Our only commercial product is ILUVIEN�, which has received marketing authorization in Austria, the United Kingdom, Portugal, France, Germany and Spain, and has been recommended for marketing authorization in Italy, for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies. DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness.
Register for EDGAR Pro and access this filing in:     
  FORM 10-K
    PART I
      ITEM 1. BUSINESS
      ITEM 1A Risk Factors
      ITEM 1B. UNRESOLVED STAFF COMMENTS
      ITEM 2. PROPERTIES
      ITEM 3. LEGAL PROCEEDINGS
      ITEM 4. MINE SAFETY DISCLOSURES
    PART II
      ITEM 5 MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED ...
      ITEM 6 SELECTED CONSOLIDATED FINANCIAL DATA
      ITEM 7 MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL ...
        Results of Operations
        Liquidity and Capital Resources
      ITEM 7A QUALITATIVE AND QUANTITATIVE DISCLOSURES ABOUT ...
      ITEM 8 FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
      ITEM 9 CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ...
      ITEM 9A CONTROLS AND PROCEDURES
      ITEM 9B Other Information
    PART III
      ITEM 10 DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
      ITEM 11 EXECUTIVE COMPENSATION
      ITEM 12 SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND ...
      ITEM 13 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND ...
      ITEM 14 PRINCIPAL ACCOUNTANT FEES AND SERVICES
    PART IV
      ITEM 15 EXHIBITS AND FINANCIAL STATEMENTS SCHEDULES
    Signatures
    REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
    BALANCE SHEET
    INCOME STATEMENT
    STOCKHOLDERS EQUITY
    CASH FLOW
    NOTES TO FINANCIAL STATEMENTS Notes to Consolidated ...
    EXHIBIT INDEX
  EXHIBIT 10.34
  EXHIBIT 23.1
    CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
  EXHIBIT 31.1
    CERTIFICATION
  EXHIBIT 31.2
    CERTIFICATION
  EXHIBIT 32.1
    CERTIFICATION
BROKERAGE PARTNERS